cyrilzakka/clinical-trials huggingface dataset:
Recruitment Maneuver After Bronchoalveolar Lavage in ARDS Patients

ARDS caused by pneumonia is one of the main reasons for ICU admission in critically ill patients, and also a common complication in patients admitted to ICU with invasive mechanical ventilation. Bronchoalveolar lavage (BAL) is the main diagnostic method for these patients, which often leads to alveolar collapse and exacerbates hypoxemia. In clinical practice, recruitment maneuver (RM) is often used immediately after BAL to prevent such a situation, but there is a lack of data on RM after BAL.


Eligibility Criteria:
Inclusion Criteria:

1. Adult patients with invasive mechanical ventilation;
2. Patients who diagnosed with ARDS according to the Berlin definition
3. There are indications for bronchoalveolar lavage

Exclusion Criteria:

1. Patients with contraindications for EIT procedures;
2. Patients with contraindications for RM;
3. Previous chronic respiratory diseases (long-term home oxygen therapy for chronic respiratory diseases such as pulmonary fibrosis or COPD);
4. Pregnancy;
5. Refusal to sign informed consent
Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

The primary objective of this study is to determine the safety and efficacy of pulsatile GnRH delivered from a iontophoretic patch (Lutrepatch) for induction of ovulation in women with anovulatory/ oligoovulatory infertility, compared to placebo and to a reference treatment with clomiphene citrate.


Eligibility Criteria:
Inclusion Criteria:

1. Females between the ages of 18 and 38 years
2. Desire to become pregnant
3. Infertile due to ovulatory dysfunction as described below:

   * Unable to conceive for at least 1 year and
   * Anovulatory (defined as 4 or fewer menstrual cycles per year) or Oligo-ovulatory (defined as menstrual cycle frequency \> 45 days)

Exclusion Criteria:

1. Requires donor oocytes or sperm
2. Two or more failed (defined as no biochemical pregnancy achieved) gonadotropin fertility treatment cycles - if previous gonadotropin success, no more than two failed subsequent cycles
3. Use of insulin-sensitizing drugs (e.g., Metformin) within 1 month prior to progesterone challenge
A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis

This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.


Eligibility Criteria:
Inclusion Criteria:

* Ability of parent or legal guardian to provide written informed consent and, if applicable, pediatric assent and compliance with study assessments for the full duration of the study
* Diagnosis of CF by sweat or genetic testing
* Between the ages of 5 and 12 years for girls and 5 and 13 years for boys
* Ability to perform pulmonary function tests in a reproducible manner, per American Thoracic Society guidelines for spirometry
* Height \<= 10th percentile for age and sex
* Prepubertal, Tanner Stage 1
* Bone age of the non-dominant hand and wrist obtained no more than 6 months prior to study entry (bone age must be \<= 10 years for girls and \<= 11 years for boys as read using the method of Greulich and Pyle)
* Adequate caloric intake (following the CFF guidelines is encouraged; caloric intake must be documented at screening using a 24-hour food diary)
* Normal thyroid function

Exclusion Criteria:

* Prior or current rhGH use
* History of short stature due to GHD
* History within the 12 months prior to screening of glucose intolerance (impaired glucose tolerance) or CF-related diabetes (CFRD) as defined by at least one of the following: fasting serum glucose of \>= 126 mg/dL on two or more occasions; fasting serum glucose of \>= 126 mg/dL plus any casual (previously called random) glucose level \>= 200 mg/dL; casual (previously called random) glucose of \>= 200 mg/dL on two or more occasions; fasting serum glucose of \<= 126 mg/dL but 2-hour post oral glucose load of 140-199 mg/dL (impaired glucose tolerance) on two or more occasions; if a subject meets the criteria for impaired glucose tolerance or CFRD in the screening glucose tolerance test, even if there is no history of impaired glucose tolerance, the subject will not be eligible for the study.
* Infection with Burkholderia cepacia
* Qualitative change in antibiotic treatment (e.g., for exacerbation of lung infection) within 14 days of study entry
* Hospitalization or treatment with systemic corticosteroids during the 30 days prior to study entry
* Inability to adhere to previously documented adequate nutrition
* Active neoplasia
* Participation in any other investigational study (including investigational drug studies) within 30 days of enrollment or during the study if in the treatment arm, except for participation in observational and questionnaire studies (untreated)
* Subjects who require, as part of the their medical care, scheduled elective hospitalizations for IV antibiotic therapy
Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer

Rationale: With 1.6 million new cases diagnosed each year and 1.3 million deaths, lung cancer is the leading cancer-related death worldwide and it represents a pressing health issue. Patients with lung cancer are more likely to experience cachexia, a severe debilitating disorder causing fatigue, weight loss, muscle wasting and associated with reduced physical function, increased chemotherapy toxicity and reduced survival. This syndrome occurring in about 80% of advanced cancer patients is the direct cause of death in about 20% of cases. However, despite the importance of cachexia in lung cancer, its mechanisms ans its relation with muscle function and effort tolerance are still unknown.

Aim: To explore muscle function, signaling pathways and its relationship to impaired functional capacity of patients with non-small-cell lung cancer(NSCLC); depending of whether they have cachexic state at diagnosis.

Methods: This study will be conducted at the Institut universitaire de cardiologie et de pneumologie de Québec. 56 patients newly diagnosed of NSCLC will be recruited and separated whether or not they have a cachexic state. The evaluation will need two visits separated by 5 days.

During the evaluation the following tests will be done:

* Anthropometric measures
* Level of daily physical activity
* Pulmonary function test
* Maximal incremental cardiopulmonary exercise test on ergocycle
* Endurance test on ergocycle
* Muscle function tests
* Magnetic stimulation
* Quadriceps biopsy


Eligibility Criteria:
Inclusion Criteria:

* Men and women with a primary lung cancer diagnosis

Exclusion Criteria:

* Already have undertaken surgery, chemotherapy or radiotherapy treatment
* Having an other cancer in the last five years
* Taking anticoagulation therapy
Dexmedetomidine and Renal Transplants

Investigators aim to retrospectively research patients undergoing renal transplants that received dexmedetomidine perioperatively to see if dexmedetomidine use protects renal function. Investigators hope to elucidate any association between renal transplant patients and perioperative dexmedetomidine administration, these include (but are not limited to) UOP, Cr/GFR, morbidity, mortality, in hospital complications and failure rate. Investigators will research both living and cadaveric renal transplants.


Eligibility Criteria:
Inclusion Criteria: Patients greater than or equal to 18 years old that underwent renal transplant at UC Davis Medical Center -

Exclusion Criteria: Patients that did not undergo renal transplants and patients less than 18 years old will be excluded from the study.

-
Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis

Rheumatoid arthritis (RA), affects between 0.3% and 1.0% of the population, it can lead to progressive joint destruction and severe disability. To date, two RA genetic susceptibility factors have been identified: HLA-DRB1-SE (Shared epitope) and PTPN22 620W alleles. The predictive value of the alleles for diagnosis of RA was previously investigated in cohorts of caucasians patients with early unclassified arthritis that showed restrained association between RA and HLA-SE. Despite the contribution of HLA to the overall genetic risk has been estimated to range from 30% to 50%, it has never been studied in the French west-Indian population.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Rheumatoid Arthritis according to ACR criteria
* Come from French West Indies (At least 3 grandparents are African-Caribbean)
* Sign written informed consent

Exclusion Criteria:

* Minor
* Patient with no Rheumatoid Arthritis according to ACR criteria
* Patient does not agree for a genetic study

For the control

Inclusion Criteria:

* Blood donor
* Sign written informed consent
* Patient with no Rheumatoid Arthritis according to ACR criteria
* Come from French West Indies (At least 3 grandparents are African-Caribbean)

Exclusion Criteria:

* Minor
* Patient does not agree for a genetic study
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival

This is a phase 2, open label, single cohort, single centre, clinical trial of neoadjuvant immunotherapy with dual inhibition of PD-1 and LAG-3 immune checkpoint pathways. The hypothesis is that neoadjuvant therapy produces a higher pathological response rate (pCR) and a longer recurrence-free survival in a cohort of treatment-naïve patients with resectable stage I (≥10 mm) to stage III Merkel cell carcinoma compared to neoadjuvant nivolumab monotherapy in Checkmate 358 (n=123, NCT02488759, historical control).

Eligibility Criteria:
Inclusion Criteria:

* Aged ≥ 18 years
* Written consent Histologically confirmed, resectable Merkel cell carcinoma with AJCC (8th ed) clinical stage I (≥ 10 mm), II, or III
* In-transit metastases are permitted if they are completely resectable
* Measurable disease according to RECIST 1.1 criteria
* Tumour amenable to core biopsy
* Previous radiotherapy permitted if there is RECIST-measurable progression of disease since the completion of radiotherapy
* ECOG 0-1
* Adequate organ function on blood pathology
* Life expectancy \>12 months
* Female patients to use effective contraception during study treatment and for 5 months after last dose.

Exclusion Criteria:

* Clinical or radiographic evidence of distant metastases
* Contraindication to nivolumab and / or relatlimab
* Prior anti-PD-1, CTLA-4, PDL-1 or LAG 3 antibody exposure, or an agent directed to another stimulatory or co-inhibitory T-cell receptor for any disease or any chemotherapy or experimental local or systemic drug treatment
* Active autoimmune disease or requirement for chronic steroid therapy other than hormone replacement therapy
* A diagnosis of immunodeficiency or chronic steroid therapy \>10 mg OD prednisone or equivalent
* Additional malignancy active within past 3 years; patients with chronic lymphocytic leukaemia can be included in this study.
* Uncontrolled cardiovascular disease or history of myocarditis - Has had an allogenic tissue/solid organ transplant
* Active Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection.
* Known HIV
* Pregnant or breast feeding females
* Concurrent medical or social conditions that may prevent the patient attending assessments or procedures per schedule
Neural Mechanisms and Efficacy of Dual Neurotechnology-aided Mirror Therapy in Chronic Stroke: Neural and Motor Plasticity, Movement Performance, Daily Function, and Quality of Life

Mirror therapy (MT) has been demonstrated, in terms of neuroplasticity, to improve sensorimotor function of paretic upper extremity (UE) in chronic stroke patients. Central and peripheral electrical stimulation techniques such as ranscranial direct current stimulation (tDCS) and functional electrical stimulation (FES) can individually enhance effects of MT, combining both of them with MT can be a potentially valuable approach to maximize neural and functional recovery post stroke. To our knowledge, no studies combined central and peripheral neural network reorganization technique with motor behavioral learning approach to investigate its possible benefit after stroke. This project will be the first to design a "dual neurotechnology-aided MT (DNA-MT)", which combines tDCS and FES with contemporary neurorehabilitation approaches (i.e., MT) to stimulate both central and peripheral nervous systems to maximize neural and functional recovery post stroke. Investigators will determine the efficacy and neurophysiological and motor mechanisms related to this novel DNA-MT approach and identify potential responders to this novel intervention.


Eligibility Criteria:
Inclusion Criteria:

* sustained a unilateral stroke with onset ≥ 3 months (Figlewski et al., 2017);
* UE Fugl-Meyer assessment (UE-FMA) score between 18 and 56 indicating mild to moderate mild motor severity (Menezes et al., 2018; Woodbury, Velozo, Richards, \& Duncan, 2013);
* aged 35 to 85 years old; and
* able to follow instructions and perform the tasks (Mini Mental State Examination ≥24).

Exclusion Criteria:

* with excessive spasticity or joint contracture of the paretic UE;
* enrolled in other rehabilitation experiments or drug studies;
* with additional neurological or psychological disorders other than stroke;
* having received Botulinum toxin injections 3 months before enrollment;
* having unstable cardiovascular status such as uncontrolled hypertension or New York Heart Association (NYHA) Class III/IV heart failure;
* having contradictions to tDCS including a history of epilepsy, migraine headache, uncontrolled medical status, being pregnant, having a pacemaker, or metal implanted in their head or body (not including dental fillings or hardware)(Meeker et al., 2019; Rossi, Hallett, Rossini, Pascual-Leone, \& Group, 2009);
* having a history of drug or alcohol abuse, dermatosis preventing tDCS from being applied, brain tumor, brain injury, arteriovenous malformation, other brain diseases (such as intracranial hypertension or cerebral edema), or are not suitable for using tDCS by the physician's assessment; and (8) having existence of skin rash, allergy or wounds at the locations where stimulation electrodes would be placed.
Examining Measurement of Behavioral Neglect Post Stroke

The purpose of this study is to examine measurement of unilateral neglect post stroke. Although a number of clinical assessments are used to measure neglect, it is unclear whether items from some of the most commonly used assessments are able to effectively and comprehensively measure neglect. This study will determine whether these assessments measure different aspects of neglect and whether items from various neglect assessments can be combined to more effectively measure neglect.

Many individuals have difficulty attending to the affected side of their body or to the affected side of space after stroke (unilateral neglect). Although a number of clinical assessments are used to measure this inattention, it is unclear whether items from some of the most commonly used assessments are able to effectively and comprehensively measure inattention. Clinical assessments provide critical information to clinicians and researchers and are used to inform treatment and document patient progress. Therefore, it is important that investigators more closely examine these existing assessments.

Individuals who demonstrate impaired attention to the affected side after stroke also have greater motor impairment than individuals who do not have impaired attention, but investigators do not know how inattention affects reaching movements using the impaired arm. This study will examine various methods used to assess inattention to the affected side after stroke and also examine how inattention affects reaching movements of the impaired arm.

Eligibility Criteria:
Inclusion Criteria:

* Unilateral hemispheric stroke
* 18 years or older

Exclusion Criteria:

* Severe aphasia
* Inability to follow 2-step directions
* Presence of other neurological disease that may impair vision or perception during performance of evaluation procedures
Measuring the Context of Healing in Chronic Pain Treatment

This project focuses on whether nonspecific factors as well as patient characteristics contribute to treatment outcome differences. The project uses assessment instruments, computerized adaptive tests (CATs), from the Patient-Reported Outcomes Measurement Information System (PROMIS®). The research team has recently developed and tested (using PROMIS methods) a set of instruments to assess non-specific factors in healing from the patient's perspective. These instruments, the Healing Encounters and Attitudes Lists (HEAL) assess the Patient-Provider Connection, Treatment Expectancy, views of the Healthcare Environment, Positive and Negative Attitudes, Spirituality, and Attitude toward Complementary and Alternative Medicine (CAM). HEAL CAT's, like other PROMIS CATs, are brief, easy to use and understand, and are designed to apply to a broad spectrum of treatments and health conditions. In this project, the investigators aim to 1) evaluate whether HEAL predicts chronic pain treatment outcomes, 2) examine heterogeneity of treatment effects based upon HEAL and PROMIS scores in integrative and conventional medicine settings, and 3) interview patients and their clinicians regarding the utility of HEAL, PROMIS and a Pain Log for enhancing communication. The investigators will administer HEAL CATs and other PROMIS CATs (depression, anxiety, sleep disturbance, fatigue and physical function) to 200 patients who are starting treatment for chronic pain in integrative medicine and conventional medicine settings. Follow-up assessments will be completed 2 and 4 months after baseline testing. The investigators will evaluate factors that may predict which patients judge themselves to be improved, the same, or worsened. Some of the possible factors that may contribute to improvement include HEAL scores, emotional distress, or the preference for CAM or conventional treatment. The investigators are also interested in learning whether patients find the assessments to be clear and useful. A subset of 50 patients and approximately 10 clinicians will complete interviews about the HEAL and PROMIS questions, and about the Pain Log developed by a patient advocacy group partner, the American Chronic Pain Association. By interviewing patients and their healthcare providers, the investigators hope to determine the clarity and acceptability of the HEAL and other assessments, and to learn whether HEAL and PROMIS summaries enhance patient-provider communication in the clinical partnership.


Eligibility Criteria:
Inclusion Criteria:

* 18 years and older
* able to read and understand English
* able to answer questionnaires on a computer
* starting a new treatment for chronic pain or having just started a new treatment within the past month
* expecting to continue their course of treatment

Exclusion Criteria:

* psychotic disorders
* substance abuse by self report
Discovering FFC-MRI Biomarkers of Alzheimer Disease

Fast Field-Cycling MRI (FFC MRI) is a new scanning technology being developed at the University of Aberdeen. Previous pilot studies by the team on osteoarthritis, breast cancer, musculoskeletal cancer, liver fibrosis, thrombosis and muscle damage have demonstrated that FFC MRI provides useful information for clinical diagnostics in a variety of pathologies.

The aim of this study is to ascertain if brain imaging with FFC MRI yields any useful information in the diagnosis and evaluation of Alzheimer's disease.

Alzheimer's disease (AD) patients and appropriate controls will be identified by consultants working with the patient group.

Potential participants will be approached by letter by their clinician. The purpose of this study will be explained to them and they will be asked for signed informed consent.

Communication between the clinical team and FFC-MRI research team will ensure that any appointment for FFC-MRI is made at a time that is convenient for the patient and clinical team.

The aim is to recruit 25 individuals with AD and 25 age matched controls.

FFC-MRI images will be acquired on dedicated equipment specifically built for the purpose of imaging human volunteers and patients. Where clinically appropriate patents will undergo other imaging procedures as part of their normal NHS care.

FFC-MRI will be compared standard clinical care data to identify regions of interest for quantitative analysis of FFC MRI data.

Anonymous personal information will be collected from the NHS patient records for stratification of the results (such as age, sex or relevant examination results)

Eligibility Criteria:
Inclusion Criteria:

* Patients with probable Alzheimer's disease, based upon cognitive testing (MMSE) and SPECT imaging.
* Controls will be participants without known cognitive impairment or Alzheimer's disease.
* Subjects capable of giving informed consent.
* Age 21 and above

Exclusion Criteria:

* MRI-incompatible condition detected in the MR screening sheet such as some metallic implanted devices (see MR screening sheet in the project files).
* Claustrophobia
* Waist circumference larger than 102 cm, due to the limited bore size of the scanner.
* Restrictions to mobility such that patients are unable to be positioned in scanner by trained research radiographer e.g. severe kyphosis
* Cognitive impairment of sufficient severity that the participant does not have capacity to give informed consent
* Pregnancy
* Persons who might not adequately understand verbal explanations or written information given in English, or who have special communication needs
* Dementia of sufficient severity that the participant cannot give informed consent